Pitavastatin

Pitavastatin
Clinical data
Trade names	Livalo, Livazo, others
AHFS/Drugs.com	Monograph
MedlinePlus	a610018
License data	US DailyMed: Pitavastatin;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	C10AA08 (WHO) C10BA13 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	60%
Protein binding	96%
Metabolism	Liver (CYP2C9, minimally)
Elimination half-life	11 hours
Excretion	Faeces
Identifiers
	IUPAC name (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid;
CAS Number	147511-69-1 ;
PubChem CID	5282452;
IUPHAR/BPS	3035;
ChemSpider	4445604 ;
UNII	M5681Q5F9P;
ChEBI	CHEBI:32020 ;
ChEMBL	ChEMBL1201753 ;
CompTox Dashboard (EPA)	DTXSID1048384 ;
ECHA InfoCard	100.171.153
Chemical and physical data
Formula	C25H24FNO4
Molar mass	421.468 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(c3ccccc3nc1C2CC2)c4ccc(F)cc4;
	InChI InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1 ; Key:VGYFMXBACGZSIL-MCBHFWOFSA-N ;
	(what is this?) (verify)

Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol lowering medication class of statins.^[1]

Pitavastatin is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis.

It was patented in 1987 and approved for medical use in 2003.^[2] It is available in Japan, South Korea and in India.^[3] In the US, it received FDA approval in 2009.^[4] Kowa Pharmaceuticals, a subsidiary of Kowa Company, is the owner of the American patent to pitavastatin.

^ Kajinami K, Takekoshi N, Saito Y (2003). "Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor". Cardiovascular Drug Reviews. 21 (3): 199–215. doi:10.1111/j.1527-3466.2003.tb00116.x. PMID 12931254.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 473. ISBN 9783527607495.
^ "Zydus Cadila launches pitavastatin in India". Archived from the original on 26 September 2017. Retrieved 28 May 2006.
^ "Pitavastatin (Livalo)--the seventh statin". The Medical Letter on Drugs and Therapeutics. 52 (1343): 57–8. July 2010. PMID 20651638.

[Kajinami-1] Kajinami K, Takekoshi N, Saito Y (2003). "Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor". Cardiovascular Drug Reviews. 21 (3): 199–215. doi:10.1111/j.1527-3466.2003.tb00116.x. PMID 12931254.

[Fis2006-2] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 473. ISBN 9783527607495.

[Zydus-3] "Zydus Cadila launches pitavastatin in India". Archived from the original on 26 September 2017. Retrieved 28 May 2006.

[Seventh-4] "Pitavastatin (Livalo)--the seventh statin". The Medical Letter on Drugs and Therapeutics. 52 (1343): 57–8. July 2010. PMID 20651638.

[1]

[2]

[3]

[4]